Trial · NCT02706886
Results by group198
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 198
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs) | Part A: SAD: Placebo | 5 | Participants | ||
| Number of Participants With Adverse Events (AEs) | Part A: SAD: Lumasiran 0.3 mg/kg | 6 | Participants | ||
| Number of Participants With Adverse Events (AEs) | Part A: SAD: Lumasiran 1.0 mg/kg | 2 | Participants | ||
| Number of Participants With Adverse Events (AEs) | Part A: SAD: Lumasiran 3.0 mg/kg | 6 | Participants | ||
| Number of Participants With Adverse Events (AEs) | Part A: SAD: Lumasiran 6.0 mg/kg | 6 | Participants | ||
| Number of Participants With Adverse Events (AEs) | Part B: MAD: Placebo | 2 | Participants | ||
| Number of Participants With Adverse Events (AEs) | Part B: MAD: Lumasiran 1.0 mg/kg qM | 8 | Participants | ||
| Number of Participants With Adverse Events (AEs) | Part B: MAD: Lumasiran 3.0 mg/kg qM | 7 | Participants | ||
| Number of Participants With Adverse Events (AEs) | Part B: MAD: Lumasiran 3.0 mg/kg q3M | 4 | Participants | ||
| Maximum Concentration (Cmax) of Lumasiran in Plasma | Part A: SAD: Lumasiran 0.3 mg/kg | Day 1 | 39.7940 | Standard Deviation 8.58882 | ng/mL |
| Maximum Concentration (Cmax) of Lumasiran in Plasma | Part A: SAD: Lumasiran 1.0 mg/kg | Day 1 | 204.3748 | Standard Deviation 111.68091 | ng/mL |
| Maximum Concentration (Cmax) of Lumasiran in Plasma | Part A: SAD: Lumasiran 3.0 mg/kg | Day 1 | 533.4527 | Standard Deviation 160.11060 | ng/mL |
| Maximum Concentration (Cmax) of Lumasiran in Plasma | Part A: SAD: Lumasiran 6.0 mg/kg | Day 1 | 1176.1302 | Standard Deviation 199.89797 | ng/mL |
| Maximum Concentration (Cmax) of Lumasiran in Plasma | Part B: MAD: Lumasiran 1.0 mg/kg qM | Day 1 | 324.1386 | Standard Deviation 489.71104 | ng/mL |
| Maximum Concentration (Cmax) of Lumasiran in Plasma | Part B: MAD: Lumasiran 3.0 mg/kg qM | Day 1 | 582.4515 | Standard Deviation 266.90105 | ng/mL |
| Maximum Concentration (Cmax) of Lumasiran in Plasma | Part B: MAD: Lumasiran 3.0 mg/kg q3M | Day 1 | 432.2798 | Standard Deviation 245.02660 | ng/mL |
| Maximum Concentration (Cmax) of Lumasiran in Plasma | Part B: MAD: Lumasiran 1.0 mg/kg qM | Day 57 | 147.6780 | Standard Deviation 67.97968 | ng/mL |
| Maximum Concentration (Cmax) of Lumasiran in Plasma | Part B: MAD: Lumasiran 3.0 mg/kg qM | Day 57 | 701.1708 | Standard Deviation 511.63001 | ng/mL |
| Maximum Concentration (Cmax) of Lumasiran in Plasma | Part B: MAD: Lumasiran 3.0 mg/kg q3M | Day 85 | 411.5613 | Standard Deviation 174.92146 | ng/mL |
| Time to Cmax (Tmax) of Lumasiran in Plasma | Part A: SAD: Lumasiran 0.3 mg/kg | Day 1 | 5.0167 | Full Range 4.000 to 8.017 | hours |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02706886/results